Roche Glycart Ag

Hoffmann-la Roche Inc.

Glycart Biotechnology Ag

Roche Glyeart Ag

F. Hoffmann-la Roche Ag

Pablo Umaña

Christian Klein

Ekkehard Moessner

Guy Georges

Wolfgang Schaefer

Stefan Seeber

Joerg Thomas Regula

Ralf Hosse

Georg Fertig

Kay-Gunnar Stubenrauch

Ekkehard Mössner

Joël Jean-Mairet

James E Bailey

Anne Freimoser-Grundschober

Peter Bruenker

Tilman Schlothauer

Thomas U Hofer

Sabine Imhof-Jung

Michael Molhoj

Valeria G Nicolini

Inja Waldhauer

Alexander Bujotzek

Wei Xu

Johannes Sam

Wolfgang Richter

Alexander Knaupp

Claudia Ferrara Koller

Stefan Klostermann

Tanja Fauti

Marina Bacac

Jens Fischer

Oliver Ast

Lydia Jasmin Hanisch

Sandra Grau-Richards

Joerg Benz

Maria Amann

Harald Duerr

Christina Claus

Valeria Lifke

Christiane Neumann

Viktor Levitski

Uwe Wessels

Tina Weinzierl

Samuel Moser

Laura Codarri Deak

Halina Trochanowska

Tobias Suter

M Sean Bailey, Legal Representative

Maria Valeria Gonzalez Nicolini

Mario Perro

Adrian Zwick

Claudia Ferrara

Jenny Tosca Thom

Christine Trumpfheller

Moritz Rapp

Alfred Zippelius

Laura Codarri-Deak

Christiane Jaeger

Ildiko Wuensche

Stephan Gasser

Laurene Pousse

Estelle Marrer-Berger

Teemu Tapani Junttila

Stefan Evers

Laura Lauener

Jose Saro

Vaios Karanikas

Jens Schreiner

Stéphane LeClair

Peter Brünker

Ursula Püntener

Ralf Jörg Hosse

Mudita Pincha

Jean-Baptiste Vallier

Alejandro Carpy Gutierrez Cirlos

Christine Kuettel

Simon Patrick Keiser

Pavel Pisa

Stephane Leclair

Eva Carina Sum

Eva Rossmann

Sara Colombetti

Michela Silacci-Melkko

Claudia Ferrera Koller

Daniela Thommen

Viktor Levitsky

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/WT1

The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Agonistic CD28 antigen binding molecules targeting Her2

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/MAGE-A4

The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecule for a costimulatory TNF receptor

The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Tumor-targeted agonistic CD28 antigen binding molecules

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9

The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Fc-free antibodies comprising two fab-fragments and methods of use

Growing community of inventors

Zurich, Switzerland

Pablo Umaña